Expression of complement factor H by lung cancer cells: Effects on the activation of the alternative pathway of complement

Cancer Research

Volumn 64, Issue 17, 2004, Pages 6310-6318

  Ajona, Daniel ^a   Castaño, Zafira ^a   Garayoa, Mercedes ^a,b   Zudaire, Enrique ^c   Pajares, Maria J ^a,b   Martinez, Alfredo ^c   Cuttitta, Frank ^c   Montuenga, Luis M ^a,b   Pio, Ruben ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CARCINOID; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPENDENT CYTOTOXICITY; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG NON SMALL CELL CANCER; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR BIOPSY; WESTERN BLOTTING;

BLOOD PROTEINS; CELL LINE, TUMOR; CELL MEMBRANE; COMPLEMENT C3B; COMPLEMENT C5A; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LUNG NEOPLASMS;

EID: 4344689094     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2328     Document Type: Article

References (57)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. Ca Cancer J Clin 2002;52:23-47.
2. Harjunpaa A, Junnikkala S, Meri S, Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000;51:634-41.
3. Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol 2002;13:609-14.
4. Jurianz K, Ziegler S, Garcia-Schuler H, et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999;36:929-39.
5. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 1998;113:173-82.
6. Liszewski MK, Atkinson JP. The complement system. In: Paul WE, editor. Fundamental Immunology, Third Edition. New York: Raven Press; 1993, p. 917-39.
7. Muller-Eberhard HJ, Schreiber RD, Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol 1980;29:1-53.
8. Schwaeble W, Zwimer J, Schulz TF, Linke RP, Dierich MP, Weiss EH, Human complement factor H: expression of an additional truncated gene product of 43 kDa in human liver. Eur J Immunol 1987;17:1485-9.
9. Friese MA, Hellwage J, Jokiranta TS, et al. Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA). Clin Exp Immunol 2000;121:406-15.
10. Serrano J, Encinas JM, Fernandez AP, et al. Distribution of immunoreactivity for the adrenomedullin binding protein, complement factor H, in the rat brain. Neuroscience 2003;116:947-62.
11. Zipfel PF, Skerka C. FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function. Immunol Today 1999;20:135-40.
12. Whaley K, Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med 1976;144:1147-63.
13. Harrison RA, Lachmann PJ. The physiological breakdown of the third component of human complement. Mol Immunol 1980;17:9-20.
14. Sim E, Wood AB, Hsiung LM, Sim RB, Pattern of degradation of human complement fragment, C3b. FEBS Lett 1981;132:55-60.
15. Malhotra R, Ward M, Sim RB, Bird MI. Identification of human complement Factor H as a ligand for L-selectin. Biochem J 1999;341:61-9.
16. DiScipio RG, Daffern PJ, Schraufstatter IU, Sriramarao P. Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). J Immunol 1998;160:4057-66.
17. Iferroudjene D, Schouft MT, Lemercier C, Gilbert D, Fontaine M. Evidence for an active hydrophobic form of factor H that is able to induce secretion of interleukin 1-beta or by human monocytes. Eur J Immunol 1991;21:967-72.
18. Nabil K, Rihn B, Jaurand MC, et al. Identification of human complement factor H as a chemotactic protein for monocytes. Biochem J 1997;326:377-83.
19. Neeleman C, Geelen SP, Aerts PC, et al. Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun 1999;67:4517-24.
20. Ram S, Sharma AK, Simpson SD, et al. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med 1998;187:743-52.
21. Ram S, McQuillen DP, Gulati S, Elkins C, Pangburn MK, Rice PA. Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J Exp Med 1998;188:671-80.
22. Diaz A, Ferreira A, Sim RB. Complement evasion by Echinococcus granulosus: sequestration of host factor H in the hydatid cyst wall. J Immunol 1997;158:3779-86.
23. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci USA 1988;85:1657-61.
24. Pio R, Martinez A, Unsworth EJ, et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 2001;276:12292-300.
25. Gasque P, Julen N, Ischenko AM, et al. Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 1992;149:1381-7.
26. Legoedec J, Gasque P, Jeanne JF, Fontaine M. Expression of the complement alternative pathway by human myoblasts in vitro: biosynthesis of C3, factor B, factor H and factor I. Eur J Immunol 1995;25:3460-6.
27. Gasque P, Thomas A, Fontaine M, Morgan BP. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J Neuroimmunol 1996;66:29-40.
28. Katz Y, Guterman M, Lahat E. Regulation of synthesis of complement proteins in HEp2 cells. Clin Immunol Immunopathol 1993;67:117-23.
29. Junnikkala S, Hakulinen J, Jarva H, et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 2002;87:1119-27.
30. Kinders R, Jones T, Root R, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998;4:2511-20.
31. Sim RB, Day AJ, Moffatt BE, Fontaine M. Complement factor I and cofactors in control of complement system convertase enzymes. Methods Enzymol 1993;223:13-35.
32. Davis LG, Kuehl WM, Battey JM. Basic methods in molecular biology, 2 edition. Norwalk, CT: Appleton & Lange, 1994. p. 322-8.
33. Sim E, Palmer MS, Puklavec M, Sim RB. Monoclonal antibodies against the complement control protein factor H (beta 1 H). Biosci Rep 1983;3:1119-31.
34. Brasoveanu LI, Altomonte M, Fonsatti E, et al. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest 1996;74:33-42.
35. Jarvis GA, Li J, Hakulinen J, et al. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 1997;71:1049-55.
36. Yu J, Caragine T, Chen S, Morgan BP, Frey AB, Tomlinson S. Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clin Exp Immunol 1999;115:13-8.
37. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 2003;131:254-63.
38. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP, Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 1996;149:129-42.
39. Varsano S, Frolkis I, Rashkovsky L, Ophir D, Fishelson Z. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation. Am J Respir Cell Mol Biol 1996;15:731-7.
40. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000;164:6075-81.
41. Maenpaa A, Junnikkala S, Hakulinen J, Timonen T, Meri S. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 1996;148:1139-52.
42. Ollert MW, David K, Bredehorst R, Vogel CW. Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b. J Immunol 1995;155:4955-62.
43. Corey MJ, Kinders RJ, Brown LG, Vessella RL. A very sensitive coupled luminescent assay for cytotoxicity and complement-mediated lysis. J Immunol Methods 1997;207:43-51.
44. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000;275:16666-72.
45. Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS. Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 2002;277:13700-8.
46. Demares MJ, Davrinche C. Prevalence of the 1.8 kb complement factor H mRNA in human lung. Immunology 1990;70:150-4.
47. Schwaeble W, Schwaiger H, Brooimans RA, et al. Human complement factor H. Tissue specificity in the expression of three different mRNA species. Eur J Biochem 1991;198:399-404.
48. Linnoila RI. Spectrum of neuroendocrine differentiation in lung cancer cell lines featured by cytomorphology, markers, and their corresponding tumors. J Cell Biochem Suppl 1996;24:92-106.
49. Bara S, Lint TF. The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages. J Immunol 1987;138:1303-9.
50. Ramos OF, Nilsson B, Nilsson K, Eggertsen G, Yefenof E, Klein E. Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b fragments. Cell Immunol 1999;119:459-69.
51. Perlmann H, Perlmann P, Schreiber RD, Muller-Eberhard HJ. Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity. J Exp Med 1981;153:1592-603.
52. Pio R, Martinez A, Cuttitta F. Cancer and diabetes: two pathological conditions in which adrenomedullin may be involved. Peptides 2001;22:1719-29.
53. Cuttitta F, Pio R, Garayoa M, et al. Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. Microsc Res Tech 2002;57:110-9.
54. Martinez A, Miller MJ, Unsworth EJ, Siegfried JM, Cuttitta F. Expression of adrenomedullin in normal human lung and in pulmonary tumors. Endocrinology 1995;136:4099-105.
55. Martinez A, Miller MJ, Catt KJ, Cuttitta F. Adrenomedullin receptor expression in human lung and in pulmonary tumors. J Histochem Cytochem 1997;45:159-64.
56. Miller MJ, Martinez A, Unsworth EJ, et al. Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. J Biol Chem 1996;271:23345-51.
57. Martinez A, Vos M, Guedez L, et al. The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst 2002;94:1226-37.